Latest News

Patients who developed ototoxicity during cisplatin treatment experienced less worsening of pure-tone audiometry thresholds in ears treated with ACOU085 compared with placebo-treated ears.

Data from the BREEZE trial support the efficacy, safety, and tolerability of the Zenflow Prostatic Spring for BPH-related LUTS.

The approval is supported by data from the phase 3 CAPItello-281 trial.

The application is supported by data from the phase 3 LITESPARK-022 trial.

In this episode of The UroOnc Minute, Carissa Chu, MD, discusses the prevalence, biology, prognostic significance, and emerging molecular targets of variant histologies in bladder cancer.

In this video, Benjamin H. Lowentritt, MD, FACS, discusses findings from the real-world OPTYX study, assessing testosterone suppression and recovery among patients receiving relugolix for advanced prostate cancer.

Long-term data from the phase 2 TROG 15.03 FASTRACK II trial support the safety and efficacy of stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Jonathan D. Harper, MD, discusses findings from a secondary analysis of the PUSH trial showing that modest increases in urine volume and lower urine osmolality were associated with reduced kidney stone recurrence, even when patients did not reach the guideline-recommended urine output target.

The approval adds another commercially available source of the PSMA-targeted radiotracer.

In this episode, Amy Pearlman, MD, and Annah J. Vollstedt, MD, discuss emerging innovations in female pelvic medicine, including implantable tibial nerve stimulation, the role of pelvic floor physical therapy, and the future of incontinence care.

In this video, Nicole L. Miller, MD, FACS, discusses her approach to assessing patients after prior treatment failure for benign prostatic hyperplasia.

The addition of aglatimagene and valacyclovir to radiotherapy with or without ADT significantly improved disease-free survival in patients with intermediate- to high-risk localized prostate cancer.

Abigail Keller, MD, shares findings showing that nadofaragene firadenovec is associated with increased urine production during instillation compared with gemcitabine/docetaxel.